View Financial HealthDocCheck 배당 및 자사주 매입배당 기준 점검 3/6DocCheck 은(는) 현재 수익률이 8.62% 인 배당금 지급 회사입니다.핵심 정보8.6%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률9.0%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향95%최근 배당 및 자사주 매입 업데이트Declared Dividend • May 20Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 6.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it covered by cash flows (227% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).모든 업데이트 보기Recent updatesDeclared Dividend • May 20Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 6.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it covered by cash flows (227% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.공고 • Apr 17+ 1 more updateDocCheck AG, Annual General Meeting, May 28, 2026DocCheck AG, Annual General Meeting, May 28, 2026, at 09:30 W. Europe Standard Time.공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €8.40, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 21x in the Healthcare Services industry in Europe. Total loss to shareholders of 59% over the past three years.Reported Earnings • Sep 26First half 2024 earnings released: EPS: €0.37 (vs €0.34 in 1H 2023)First half 2024 results: EPS: €0.37 (up from €0.34 in 1H 2023). Revenue: €24.4m (down 6.8% from 1H 2023). Net income: €1.87m (up 10% from 1H 2023). Profit margin: 7.7% (up from 6.5% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.New Risk • Sep 25New major risk - Revenue and earnings growthEarnings have declined by 4.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€37.8m market cap, or US$42.1m).Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€45.7m market cap, or US$48.6m).Reported Earnings • Oct 05First half 2023 earnings released: EPS: €0.34 (vs €0.42 in 1H 2022)First half 2023 results: EPS: €0.34 (down from €0.42 in 1H 2022). Revenue: €26.2m (down 11% from 1H 2022). Net income: €1.70m (down 19% from 1H 2022). Profit margin: 6.5% (down from 7.1% in 1H 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.New Risk • Jul 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€53.4m market cap, or US$58.9m).Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Healthcare Services industry in Germany. Total returns to shareholders of 52% over the past three years.Buying Opportunity • Nov 12Now 25% undervaluedOver the last 90 days, the stock is up 5.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 39%.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to €14.80, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 25x in the Healthcare Services industry in Germany. Total returns to shareholders of 76% over the past three years.Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).Buying Opportunity • May 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 28%. The fair value is estimated to be €22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 61%.Reported Earnings • Apr 16Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: €2.27 (up from €1.83 in FY 2020). Revenue: €86.4m (up 37% from FY 2020). Net income: €11.4m (up 24% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 65%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).Reported Earnings • Apr 18Full year 2020 earnings released: EPS €1.83 (vs €0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €63.7m (up 97% from FY 2019). Net income: €9.20m (up 193% from FY 2019). Profit margin: 14% (up from 9.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.80, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 51x in the Healthcare Services industry in Germany. Total returns to shareholders of 151% over the past three years.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to €26.80, the stock is trading at a trailing P/E ratio of 31x, up from the previous P/E ratio of 26.6x. This compares to an average P/E of 42x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 183%.Is New 90 Day High Low • Feb 05New 90-day high: €26.00The company is up 53% from its price of €17.00 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 3.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day high: €24.00The company is up 48% from its price of €16.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to €23.60, the stock is trading at a trailing P/E ratio of 27.1x, up from the previous P/E ratio of 23.4x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 160%.Is New 90 Day High Low • Nov 11New 90-day high: €22.60The company is up 64% from its price of €13.80 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period.Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 35% share price gain to €22.60, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 156%.Is New 90 Day High Low • Oct 08New 90-day high: €16.30The company is up 58% from its price of €10.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: AJ91 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: AJ91 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장DocCheck 배당 수익률 vs 시장AJ91의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (AJ91)8.6%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Healthcare Services)1.8%분석가 예측 (AJ91) (최대 3년)n/a주목할만한 배당금: AJ91 의 배당금( 8.62% )은 German 시장에서 배당금 지급자의 하위 25%( 1.54% )보다 높습니다.고배당: AJ91 의 배당금( 8.62% )은 German 시장( 4.69% )주주 대상 이익 배당수익 보장: 지급 비율 ( 95.1% )이 높기 때문에 AJ91 의 배당금 지급은 수익으로 잘 충당되지 않습니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 226.7% )이 높기 때문에 AJ91 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 13:49종가2026/07/31 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DocCheck AG는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Declared Dividend • May 20Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 6.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it covered by cash flows (227% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.
Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).
Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).
Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).
Declared Dividend • May 20Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 6.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it covered by cash flows (227% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
공고 • Apr 17+ 1 more updateDocCheck AG, Annual General Meeting, May 28, 2026DocCheck AG, Annual General Meeting, May 28, 2026, at 09:30 W. Europe Standard Time.
공고 • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €8.40, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 21x in the Healthcare Services industry in Europe. Total loss to shareholders of 59% over the past three years.
Reported Earnings • Sep 26First half 2024 earnings released: EPS: €0.37 (vs €0.34 in 1H 2023)First half 2024 results: EPS: €0.37 (up from €0.34 in 1H 2023). Revenue: €24.4m (down 6.8% from 1H 2023). Net income: €1.87m (up 10% from 1H 2023). Profit margin: 7.7% (up from 6.5% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
New Risk • Sep 25New major risk - Revenue and earnings growthEarnings have declined by 4.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€37.8m market cap, or US$42.1m).
Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€45.7m market cap, or US$48.6m).
Reported Earnings • Oct 05First half 2023 earnings released: EPS: €0.34 (vs €0.42 in 1H 2022)First half 2023 results: EPS: €0.34 (down from €0.42 in 1H 2022). Revenue: €26.2m (down 11% from 1H 2022). Net income: €1.70m (down 19% from 1H 2022). Profit margin: 6.5% (down from 7.1% in 1H 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€53.4m market cap, or US$58.9m).
Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Healthcare Services industry in Germany. Total returns to shareholders of 52% over the past three years.
Buying Opportunity • Nov 12Now 25% undervaluedOver the last 90 days, the stock is up 5.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 39%.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to €14.80, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 25x in the Healthcare Services industry in Germany. Total returns to shareholders of 76% over the past three years.
Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).
Buying Opportunity • May 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 28%. The fair value is estimated to be €22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 61%.
Reported Earnings • Apr 16Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: €2.27 (up from €1.83 in FY 2020). Revenue: €86.4m (up 37% from FY 2020). Net income: €11.4m (up 24% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 65%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).
Reported Earnings • Apr 18Full year 2020 earnings released: EPS €1.83 (vs €0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €63.7m (up 97% from FY 2019). Net income: €9.20m (up 193% from FY 2019). Profit margin: 14% (up from 9.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.80, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 51x in the Healthcare Services industry in Germany. Total returns to shareholders of 151% over the past three years.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to €26.80, the stock is trading at a trailing P/E ratio of 31x, up from the previous P/E ratio of 26.6x. This compares to an average P/E of 42x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 183%.
Is New 90 Day High Low • Feb 05New 90-day high: €26.00The company is up 53% from its price of €17.00 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day high: €24.00The company is up 48% from its price of €16.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to €23.60, the stock is trading at a trailing P/E ratio of 27.1x, up from the previous P/E ratio of 23.4x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 160%.
Is New 90 Day High Low • Nov 11New 90-day high: €22.60The company is up 64% from its price of €13.80 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period.
Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 35% share price gain to €22.60, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 156%.
Is New 90 Day High Low • Oct 08New 90-day high: €16.30The company is up 58% from its price of €10.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.